http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#Head
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#assertion
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#provenance
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#pubinfo
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#assertion
http://purl.obolibrary.org/obo/DOID_1920
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1920
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB11560
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
http://www.w3.org/2000/01/rdf-schema#label
zurampic is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone s ee clinical studies 14 zurampic is a urat1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone 1 limitations of use zurampic is not recommended for the treatment of asymptomatic hyperuricemia 1 1 zurampic should not be used as monotherapy 1 1 5 1 zurampic is not recommended for the treatment of asymptomatic hyperuricemia zurampic should not be used as monotherapy see warnings and precautions 5 1
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB11560
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#provenance
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#pubinfo
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig
http://purl.org/nanopub/x/hasSignature
TCktFV5r6rSCbj7Zv1K4VQXaDLk9+3W9CEgmJZqsbGrzf6H5nlQxCfPWrGn1f38drns6pgwm3d7m8OXU/8zOk1+SpSTBr6Gdl1nACEq7QSnCi60IyjVLySEkHmH4bU4tb4kdapUVyA9Wk81iRxMWXRSmdeZRIQxEz/TzPTuTbm8=
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://purl.org/dc/terms/created
2021-06-12T12:52:49.021+02:00
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs